Britain approves world's first gene therapy Casgevy for sickle cell disease and thalassemia
The UK drug regulator says it approved Casgevy for patients with sickle cell disease and thalassemia who are 12 years old and over
citynews
6
The UK drug regulator says it approved Casgevy for patients with sickle cell disease and thalassemia who are 12 years old and over
